ArticleBioresources and bioprocessing2022
Construction of an Escherichia coli cell factory to synthesize taxadien-5α-ol, the key precursor of anti-cancer drug paclitaxel.
Article in Bioresources and bioprocessing, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 35 citations in OpenAlex.
- Multi-omics-guided discovery of CYP5035 enables heterologous production and engineering of pachymic acid in yeast.Journal of biological engineering · 2026Article
- Engineering Salvia miltiorrhiza hairy roots as a scalable platform for high-yield production of paclitaxel and ginsenoside precursors.Plant communications · 2026Article
- The biosynthesis and diversity of taxanes: From pathway elucidation to engineering and synthetic biology.Plant communications · 2025Review
- Comprehensive strategies for paclitaxel production: insights from plant cell culture, endophytic microorganisms, and synthetic biology.Horticulture research · 2025Article
- OptoLacI: optogenetically engineered lactose operon repressor LacI responsive to light instead of IPTG.Nucleic acids research · 2024Article
- Construction of lignan glycosides biosynthetic network in Escherichia coli using mutltienzyme modules.Microbial cell factories · 2024Article
- Enhancing the biosynthesis of taxadien-5α-yl-acetate in Escherichia coli by combinatorial metabolic engineering approaches.Bioresources and bioprocessing · 2024Article
- Way to efficient microbial paclitaxel mass production.Synthetic and systems biotechnology · 2023Review
- Construction and optimization of a biocatalytic route for the synthesis of neomenthylamine from menthone.Bioresources and bioprocessing · 2023Article
- Production of Phenylacetylcarbinol via Biotransformation Using the Co-Culture ofJournal of fungi (Basel, Switzerland) · 2023Article
- Plants as the Extended Phenotype of Endophytes-The Actual Source of Bioactive Compounds.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Paclitaxel (Taxol™), an alkaloid of diterpenoid family, is one of the most widely used anti-cancer drugs due to its effectiveness against a variety of tumors. Rather than directly extraction and chemical synthesis of paclitaxel or its intermediates from yew plants, construction of a microbial cell factory for paclitaxel biosynthesis will be more efficient and sustainable. The challenge for biosynthesis of paclitaxel lies on the insufficient precursor, such as taxadien-5α-ol. In this study, we report a recombinant Escherichia coli strain constructed with a heterologous mevalonate pathway, a taxadiene synthase from yew, and a cytochrome P450-mediated oxygenation system for the de novo production of taxadien-5α-ol, the first product of the multi-step taxadiene oxygenation metabolism. The key enzymes including taxadiene synthases and cytochrome P450 reductases were screened, and the linker for fusing taxadiene-5α-hydroxylase with its reductase partner cytochrome P450 reductase was optimized. By reducing the metabolic burden and optimizing the fermentation conditions, the final production of total oxygenated taxanes was raised up to 27 mg L
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.